This randomized phase 3 trial explores repeated focused radiation to control disease and spare patients with renal cell carcinoma from systemic therapy for months or even years
The phase III PROSPER RCC clinical trial demonstrated that priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma